[go: up one dir, main page]

WO2020234423A1 - Sel d'acide maléique et d'acide fumarique siponimod - Google Patents

Sel d'acide maléique et d'acide fumarique siponimod Download PDF

Info

Publication number
WO2020234423A1
WO2020234423A1 PCT/EP2020/064211 EP2020064211W WO2020234423A1 WO 2020234423 A1 WO2020234423 A1 WO 2020234423A1 EP 2020064211 W EP2020064211 W EP 2020064211W WO 2020234423 A1 WO2020234423 A1 WO 2020234423A1
Authority
WO
WIPO (PCT)
Prior art keywords
siponimod
maleic acid
solid form
salt
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2020/064211
Other languages
English (en)
Inventor
Bohumil Dymacek
Jiri PARTL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Priority to EP20726476.3A priority Critical patent/EP3972954A1/fr
Publication of WO2020234423A1 publication Critical patent/WO2020234423A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to salts of the compound Siponimod.
  • S1P1 lysophosphobpid EDG1 receptor ligand that is useful for treatment of immunological disorders. Fumaric acid salt of siponimod is now ongoing pre-registration for use in the treatment secondary progressive multiple sclerosis.
  • Siponimod was first disclosed in W02004/103306 by Novartis.
  • Hemifumarate salt of Siponimod i.e. ratio Siponimod: Fumaric acid is 1 :0.5
  • solid forms A, B, C, D and E of the hemifurate salt are disclosed in WO2010/080409 by Novartis.
  • HC1 salt, malate salt, oxalate salt, tartrate salt and their crystalline forms are disclosed in W02010/080455 by Novartis.
  • the presented invention relates to solid forms of Siponimod fumaric acid (1 : 1) salt.
  • the presented invention relates to a solid form of Siponimod fumaric acid (1: 1) salt, Form 1, characterized by XRPD pattern having 2Q values 7.1°, 12.1°, 16.4° and 17.9° 2Q (+ 0.2 degrees 2Q).
  • the presented invention also relates to a process for preparation of Siponimod fumaric acid (1 :1) salt, Form 1, comprising:
  • the presented invention further relates to Siponimod maleic acid (1 : 1) salt and solid forms thereof.
  • the presented invention relates to a solid form of Siponimod maleic acid (1 : 1) salt,
  • Form 1 characterized by XRPD pattern having 2Q values 3.6°, 15.6° and 16.7° 2Q (+ 0.2 degrees 2Q).
  • the presented invention also relates to a process for preparation of Siponimod maleic acid (1 :1) salt, Form 1, comprising:
  • the presented invention also relates to a solid form of Siponimod maleic acid (1 : 1) salt, Form 3, characterized by XRPD pattern having 2Q values 12.9°, 18.0° and 19.2° 2Q (+ 0.2 degrees 2Q).
  • the presented invention also relates to a process for preparation of Siponimod maleic acid (1 :1) salt, Form 3, comprising:
  • the presented invention further relates to a solid form of Siponimod maleic acid (1 : 1) salt, Form 4, characterized by XRPD pattern having 2Q values 12.7°, 17.6° and 20.4° 2Q (+ 0.2 degrees 2Q).
  • the presented invention also relates to a process for preparation of Siponimod maleic acid (1 :1) salt, Form 4, comprising:
  • the presented invention further relates to a solid form of Siponimod maleic acid (1 : 1) salt, Form 8, characterized by XRPD pattern having 2Q values 6.0°, 7.1°, 16.6° and 21.2° 2Q (+ 0.2 degrees 2Q).
  • the presented invention also relates to a process for preparation of Siponimod maleic acid (1 :1) salt, Form 8, comprising contacting Siponimod maleic acid salt with water.
  • the solid salts of Siponimod have lower water activity and therefore improved stability in comparison with prior art Siponimod salts.
  • the solid salts of Siponimod have also better flowability in comparison with prior art salts.
  • Figure 1 XRPD pattern of solid Form 1 of Siponimod Fumaric acid (1: 1) salt
  • Figure 2 DSC pattern of solid Form 1 of Siponimod Fumaric acid (1: 1) salt
  • Figure 8 DSC pattern of solid Form 3 of Siponimod Maleic acid (1: 1) salt
  • Figure 9 XRPD pattern of solid Form 4 of Siponimod Maleic acid (1 : 1) salt
  • Figure 10 DSC pattern of solid Form 4 of Siponimod Maleic acid (1 : 1) salt
  • Figure 11 XRPD pattern of solid Form 5 of Siponimod Maleic acid (1 : 1) salt
  • Figure 12 DSC pattern of solid Form 5 of Siponimod Maleic acid (1 : 1) salt
  • Figure 15 XRPD pattern of solid Form 7 of Siponimod Maleic acid (1 : 1) salt
  • Figure 16 XRPD pattern of solid Form 2 of Siponimod Maleic acid (1 : 1) salt
  • Figure 17 DSC pattern of solid Form 2 of Siponimod Maleic acid (1 : 1) salt
  • Figure 20 XRPD pattern of solid Form 9 of Siponimod Maleic acid (1 : 1) salt
  • Figure 21 DSC pattern of solid Form 9 of Siponimod Maleic acid (1 : 1) salt DETAILED DESCRIPTION OF THE INVENTION
  • the presented invention relates to Siponimod Fumaric acid salts (1 : 1) and solid form thereof.
  • the invention relates to a solid form of Siponimod fumaric acid (1 : 1) salt, Form 1, characterized by XRPD pattern having 2Q values 7.1°, 12.1°, 16.4° and 17.9° 2Q (+ 0.2 degrees 2Q).
  • the solid form of Siponimod fumaric acid (1: 1) salt, Form 1 can be also characterized by XRPD pattern having 2Q values 7.1°, 10.7°, 12.1°, 13.6°, 15.5°, 16.4° and 17.9° 2Q (+ 0.2 degrees 2Q).
  • the Form 1 can be further characterized by XRPD 2Q values (+ 0.2 degrees 2Q) stated in following table:
  • the Form 1 can be also characterized by XRPD pattern depicted in Figure 1 and DSC pattern depicted in Figure 2.
  • the Form 1 can be prepared by a process comprising:
  • Siponimod used in step a. is preferably amorphous.
  • the alcohol in step a. can be selected from methanol or ethanol or 1 -propanol or 2-propanol or butanol or tert-butanol, preferably it is ethanol.
  • the concentration of Siponimod in ethanol can be between 0.08 g/ml and 0.8 g/ml, preferably it is between 0.1 and 0.5 g/ml.
  • the molar ratio between Siponimod and Fumaric acid can be between 1 :0.5 and 1 : 1.5, preferably it is between 1: 1 and 1 : 1.1.
  • the mixture can be heated to dissolve both Siponimod and Fumaric acid in step a.
  • the mixture is either cooled in step b. to a temperature higher than 15°C and the solid is isolated or the solvent can be distilled off in the step b to isolate the solid.
  • the mixture is preferably heated to a temperature between 40°C and 80°C in step a. and stirred at this temperature for between 10 and 120 minutes, preferably for between 20 and 60 minutes.
  • the mixture can be then either cooled to a temperature between 15°C and 30°C, preferably to a temperature between 20°C and 30°C and stirred at this temperature for between 10 and 120 minutes, preferably for between 20 and 60 minutes to precipitate the solid Form 1.
  • the solid Form 1 can be prepared by a process where the isolating step b. comprises concentrating of the mixture of step a., preferably at an elevated temperature, for example between 40°C and 80°C.
  • the solid Form 1 of Siponimod fumaric acid (1 : 1) salt can be isolated by any suitable technique, for example by filtration and dried.
  • Siponimod preferably amorphous
  • Fumaric acid in molar ratio between 1 : 1 and 1: 1.5, preferably it is between 1 : 1 and 1: 1.1 in 2-propanol
  • concentration of Siponimod in 2-propanol can be between 0.08 g/ml and 0.8 g/ml, preferably it is between 0.1 and 0.5 g/ml, at an elevated temperature, preferably between 50°C and 90°C and stirred at this temperature for between 10 and 120 minutes, preferably for between 20 and 60 minutes and the solution is subsequently cooled to between -30°C and 10°C, preferably between 0°C and 10°C and stirred at this temperature for between 3 and 48 hours, solid Form 2 of Siponimod fumaric acid (1 : 1) salt is obtained.
  • the solid Form 2 can be characterized by XRPD 2Q values (+ 0.2 degrees 2Q) stated in following table:
  • the solid Form 2 can be also characterized by XRPD pattern depicted in Figure 3 and DSC pattern depicted in Figure 4.
  • the invention further relates to Siponimod maleic acid (1: 1) salt and solid forms thereof.
  • Solid Siponimod maleic acid (1: 1) salt, Form 1 can be characterized by XRPD pattern having 2Q values 3.6°, 15.6° and 16.7° 2Q (+ 0.2 degrees 2Q).
  • the solid Siponimod maleic acid (1: 1) salt Form 1 can be also characterized by XRPD pattern having 2Q values 3.6°, 8.3°, 14.8°, 15.6° and 16.7° 2Q (+ 0.2 degrees 2Q).
  • the solid Siponimod maleic acid (1: 1) salt Form 1 can be also characterized by XRPD pattern depicted in Figure 5 and DSC pattern depicted in Figure 6.
  • the solid Siponimod maleic acid (1: 1) salt Form 1 can be prepared by a process comprising: a. Contacting Siponimod and Maleic acid with a solvent selected from
  • Siponimod used in step a. is preferably amorphous.
  • the solvent used in step a. is preferably isopropylacetate that not only provide the solid Form 1 but also excellently increases the purity of obtained solid form after isolation.
  • the concentration of Siponimod in the solvent can be between 0.04 g/ml and 0.8 g/ml, preferably it is between 0.2 g/ml and 0.6 g/ml.
  • the molar ration between Siponimod and Maleic acid can be between 1 :0.5 and 1 : 1.5, preferably it is between 1 : 1 and 1 :1.1.
  • Siponimod and Maleic acid can be contacted with the solvent at a temperature between 20°C and 50°C, preferably at a temperature between 20°C and 30°C.
  • the isolating step b. can be performed by mixing the mixture for between 10 and 120 minutes, preferably for between 15 and 45 minutes or by an addition of for example an ether, such as diethyl ether or methyl tert-butyl ether and stirring the suspension for between 10 and 120 minutes, preferably for between 15 and 45 minutes.
  • the precipitated solid can be separated by any suitable technique, for example by filtration and dried.
  • the solid Siponimod maleic acid (1: 1) salt Form 1 can be also prepared by a process comprising:
  • the ratio (w/w) of ethanol or methanol and water can be between 1.1 : 1 and 1.6: 1, preferably it is between 1.2: 1 and 1 :4:1.
  • the concentration of Siponimod in the mixture can be between 0.015 g/ml and 0.05 g/ml.
  • the molar ration between Siponimod and Maleic acid can be between 1 :0.5 and 1 : 1.5, preferably it is between 1 : 1 and 1 : 1.5.
  • Siponimod can be dissolved in the mixture at an elevated temperature, for example between 40°C and 55°C. The mixture can be then cooled to a temperature between 20°C and 30°C.
  • Maleic acid is added either as solid or can be added as a mixture with methanol or ethanol.
  • the mixture is seeded with Form 1 of Siponimod Maleic acid (1 : 1) salt.
  • the amount of seed can be about 2-5% (weight) w.r.t. Siponimod.
  • the isolating step b. can be performed by slowly (in the course for example 2-3 hours) cooling the mixture to a temperature between 0°C and 20°C, preferably to a temperature between 10°C and 15°C and mixing the mixture for between 10 and 120 minutes, preferably for between 15 and 45 minutes.
  • the precipitated solid can be separated by any suitable technique, for example by filtration and dried.
  • the presented invention also relates to solid Siponimod maleic acid (1: 1) salt, Form 2, that can be characterized by XRPD pattern having 2Q values 8.4°, 13.1° and 17.7° 2Q (+ 0.2 degrees 2Q).
  • the solid Siponimod maleic acid (1 : 1) salt Form 2 can be also characterized by XRPD pattern having 2Q values 4.2°, 8.4°, 13.1°, 14.8° and 17.7° 2Q (+ 0.2 degrees 2Q).
  • the solid Siponimod maleic acid (1 : 1) salt Form 2 can be also characterized by XRPD 2Q values
  • the solid Siponimod maleic acid (1: 1) salt Form 2 can be also characterized by XRPD pattern depicted in Figure 16 and DSC pattern depicted in Figure 17.
  • the solid Form 2 can be prepared by a process comprising:
  • the concentration of Siponimod in the alcohol can be between 0.08 g/ml and 1 g/ml, preferably between 0.1 and 0.5 g/ml.
  • the molar ratio between Siponimod and Maleic acid can be between 1 :0.5 and 1 : 1.5, preferably it is between 1 : 1 and 1 : 1.1.
  • the mixture at step b. can be concentrated for example under vacuum at a temperature between 20°C and 50°C.
  • the concentration of the rest in the ether solvent can be between 0.025 g/ml and 1 mg/ml.
  • the mixture can be optionally left without stirring to crystallize or can be stirred to crystallize.
  • the crystallized solid can be separated by any suitable technique, for example by filtration and dried.
  • the presented invention further relates to solid Siponimod maleic acid (1: 1) salt, Form 3, that can be characterized by XRPD pattern having 2Q values 12.9°, 18.0° and 19.2° 2Q (+ 0.2 degrees 2Q).
  • the solid Siponimod maleic acid (1 : 1) salt Form 3 can be also characterized by XRPD pattern having 2Q values 7.5°, 8.1°, 12.9°, 18.0° and 19.2° 2Q (+ 0.2 degrees 2Q).
  • the solid Siponimod maleic acid (1: 1) salt Form 3 can be also characterized by XRPD 2Q values (+ 0.2 degrees 2Q) stated in following table:
  • the solid Siponimod maleic acid (1: 1) salt Form 3 can be also characterized by XRPD pattern depicted in Figure 7 and DSC pattern depicted in Figure 8.
  • the solid Form 3 can be prepared by a process comprising:
  • Siponimod used in step a. is preferably amorphous.
  • the concentration of Siponimod in methyl tert-butyl ether can be between 0.01 g/ml and 0.1 g/ml, preferably between 0.02 g/ml and 0.08 g/ml.
  • the molar ration between Siponimod and Maleic acid can be between 1 :0.5 and 1 : 1.5, preferably it is between 1 : 1 and 1 : 1.1.
  • Siponimod and Maleic acid can be contacted with the solvent at a temperature between 20°C and 50°C, preferably at a temperature between 20°C and 30°C. The mixture is then stirred at this temperature for between 1 and 50 hours, preferably for between 24 and 48 hours to precipitate the solid Form 3.
  • the precipitated solid can be separated by any suitable technique, for example by filtration and dried.
  • the invention also relates to solid Siponimod maleic acid (1: 1) salt, Form 4, that can be characterized by XRPD pattern having 2Q values 12.7°, 17.6° and 20.4° 2Q (+ 0.2 degrees 2Q).
  • the solid Siponimod maleic acid (1: 1) salt Form 4 can be also characterized by XRPD pattern having 2Q values 7.2°, 12.7°, 13.1°, 16.8°, 17.6° and 20.4° 2Q ( ⁇ 0.2 degrees 2Q).
  • the solid Siponimod maleic acid (1 : 1) salt Form 4 can be also characterized by XRPD 2Q values (+ 0.2 degrees 2Q) stated in following table:
  • the solid Siponimod maleic acid (1: 1) salt Form 4 can be also characterized by XRPD pattern depicted in Figure 9 and DSC pattern depicted in Figure 10.
  • the solid Form 4 can be prepared by a process comprising:
  • Siponimod used in step a. is preferably amorphous.
  • the concentration of Siponimod in cyclohexane can be between 0.01 g/ml and 0.1 g/ml, preferably between 0.02 g/ml and 0.08 g/ml.
  • the molar ration between Siponimod and Maleic acid can be between 1 :0.5 and 1 : 1.5, preferably it is between 1 : 1 and 1 :1.1.
  • Siponimod and Maleic acid can be contacted with the solvent at a temperature between 20°C and 50°C, preferably at a temperature between 20°C and 30°C. The mixture is then stirred at this temperature for between 1 and 50 hours, preferably for between 24 and 48 hours to precipitate the solid Form 4.
  • the precipitated solid can be separated by any suitable technique, for example by filtration and dried.
  • the solid Form 4 can be also prepared by a process comprising:
  • the acetate can be selected from methylacetate or ethylacetate or propylacetate or isopropylacetate or butylacetate or isobutylacetate or a mixture thereof, preferably it is isopropylacetate.
  • concentration of Siponimod in the acetate can be between 0. lg/ml and 0.3 g/ml.
  • the molar ration between Siponimod and Maleic acid can be between 1 :0.5 and
  • Siponimod is mixed with the acetate preferably at a temperature between 20°C and 25°C.
  • Maleic acid is added either in solid form or in form of a solution.
  • the mixture can be warmed to a temperature between 60°C and 90°C to obtain a solution.
  • the solution is then cooled to a temperature between -10°C and 30°C, preferably between 20°C and 25°C and stirred at this temperature for between 2 and 20 hours.
  • the mixture can be then optionally cooled to a temperature between -10°C and 10°C and stirred at this temperature for between 1 and 10 hours to obtain a suspension.
  • the precipitated solid can be separated by any suitable technique, for example by filtration and dried.
  • the presented invention further related to solid Siponimod maleic acid (1: 1) salt, Form 5.
  • Siponimod preferably amorphous, and Maleic acid are dissolved in methanol (step a.)
  • the mixture is concentrated to dryness (step b.)
  • an acetate is added to the rest (step c.)
  • the solid is isolated (step d.) and dried, Form 5 of Siponimod maleic acid (1: 1) salt is obtained.
  • the concentration of Siponimod in methanol can be between 0.1 g/ml and 1 g/ml, preferably between 0.2 g/ml and 0.8 g/ml.
  • the molar ration between Siponimod and Maleic acid can be between 1 :0.5 and 1 : 1.5, preferably it is between 1: 1 and 1 : 1.1.
  • Siponimod and Maleic acid can be dissolved at a temperature between 20°C and 50°C, preferably at a temperature between 20°C and 30°C.
  • the mixture is concentrated (step b.) preferably as a temperature between 20°C and 40°C and under vacuum.
  • an acetate such as ethyl acetate or methyl acetate or butyl acetate or tert-butyl acetate, preferably ethylacetate, is added to the rest.
  • Volume ratio between added acetate and methanol used in step a. can be between 1 : 1 and 2: 1, preferably it is between 1.4: 1 and 1.7: 1.
  • the mixture was left without stirring to crystallize for between 1 and 10 hours.
  • the crystallized solid can be separated by any suitable technique, for example by filtration
  • Form 5 of Siponimod maleic acid (1 : 1) salt can be characterized XRPD 2Q values (+ 0.2 degrees 2Q) stated in following table:
  • the solid Siponimod maleic acid (1: 1) salt Form 5 can be also characterized by XRPD pattern depicted in Figure 11 and DSC pattern depicted in Figure 12.
  • Siponimod preferably amorphous, and Maleic acid are dissolved in methanol (step a.)
  • the mixture is concentrated to dryness (step b.)
  • water is added to the rest (step c.)
  • the solid is isolated (step d.) and dried, Form 6 of Siponimod maleic acid (1: 1) salt is obtained.
  • concentration of Siponimod in methanol can be between 0.1 g/ml and 1 g/ml, preferably between 0.2 g/ml and 0.8 g/ml.
  • the molar ration between Siponimod and Maleic acid can be between 1 :0.5 and 1 : 1.5, preferably it is between 1: 1 and 1 : 1.1.
  • Siponimod and Maleic acid can be dissolved at a temperature between 20°C and 50°C, preferably at a temperature between 20°C and 30°C.
  • the mixture is concentrated (step b.) preferably as a temperature between 20°C and 40 °C and under vacuum.
  • step c. water is added to the rest.
  • the concentration of the rest in water can be between 0.08 g/ml and 1 g/ml, preferably between 0.1 g/ml and 1 g/ml.
  • the mixture was left without stirring to crystallize for between 1 and 10 hours.
  • the crystallized solid can be separated by any suitable technique, for example by filtration and dried.
  • Form 6 of Siponimod maleic acid (1 : 1) salt can be characterized XRPD 2Q values (+ 0.2 degrees 2Q) stated in following table:
  • the solid Siponimod maleic acid (1: 1) salt Form 6 can be also characterized by XRPD pattern depicted in Figure 13 and DSC pattern depicted in Figure 14.
  • Form 7 of Siponimod maleic acid (1 : 1) is obtained.
  • Form 7 of Siponimod maleic acid (1 :1) salt can be characterized XRPD 2Q values (+ 0.2 degrees 2Q) stated in following table:
  • the solid Siponimod maleic acid (1: 1) salt Form 7 can be also characterized by XRPD pattern depicted in Figure 15.
  • the invention further relates to solid Siponimod maleic acid (1: 1) salt, Form 8, that can be characterized by XRPD pattern having 2Q values 6.0°, 7.1°, 16.6° and 21.2° 2Q (+ 0.2 degrees 2Q).
  • the solid Siponimod maleic acid (1 : 1) salt Form 8 can be also characterized by XRPD pattern having 2Q values 6.0°, 7.1°, 13.1°, 15.8°, 16.6° and 21.2° 2Q (+ 0.2 degrees 2Q).
  • the solid Siponimod maleic acid (1: 1) salt Form 8 can be also characterized by XRPD
  • the solid Siponimod maleic acid (1: 1) salt Form 8 can be also characterized by XRPD pattern depicted in Figure 18 and DSC pattern depicted in Figure 19.
  • the solid Form 8 of Siponimod maleic acid (1: 1) salt can be prepared by a process comprising contacting Siponimod maleic acid salt with water.
  • the Siponimod maleic acid salt, Form 8 is monohydrate, i.e. it contains 2.7% of water according to TGA.
  • the invention also relates to solid Siponimod maleic acid (1: 1) salt, Form 9, that can be characterized by XRPD pattern having 2Q values 7.3°, 9.5°, 17.7° and 18.8° 2Q (+ 0.2 degrees 2Q).
  • the solid Siponimod maleic acid (1: 1) salt Form 9 can be also characterized by XRPD pattern having 2Q values 7.3°, 9.5°, 12.2°, 17.7°, 18.8° and 22.0° 2Q (+ 0.2 degrees 2Q).
  • the solid Siponimod maleic acid (1 : 1) salt Form 9 can be also characterized by XRPD 2Q values (+ 0.2 degrees 2Q) stated in following table:
  • the solid Siponimod maleic acid (1: 1) salt Form 9 can be also characterized by XRPD pattern depicted in Figure 20 and DSC pattern depicted in Figure 21.
  • the solid Form 9 can be prepared by a process comprising:
  • the ratio (w/w) of ethanol or methanol and water can be between 1.1 : 1 and 1.6: 1, preferably it is between 1.2: 1 and 1 :4:1.
  • the concentration of Siponimod in the mixture can be between 0.02 g/ml and 0.05 g/ml.
  • the molar ration between Siponimod and Maleic acid can be between 1 :0.5 and 1 : 1.5, preferably it is between 1 : 1 and 1 : 1.5.
  • Siponimod can be dissolved in the mixture at an elevated temperature, for example between 40°C and 55°C. The mixture can be then cooled to a temperature between 20°C and 30°C. To the mixture Maleic acid is added either as solid or can be added as a mixture with methanol or ethanol.
  • the isolating step b. can be performed by cooling the mixture to a temperature between 0°C and 20°C, preferably to a temperature between 10°C and 15°C and mixing the mixture for between 10 and 120 minutes, preferably for between 15 and 45 minutes.
  • the precipitated solid can be separated by any suitable technique, for example by filtration and dried.
  • the solid Form 9 of Siponimod maleic acid (1: 1) salt can be also prepared by a process comprising contacting Siponimod maleic acid salt with water for a long term, for example 1/2 year.
  • the solid Forms 1 or 2 of Siponimod Fumaric acid (1: 1) salt or solid Forms 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 of Siponimod maleic acid (1: 1) salt can be processed into a suitable pharmaceutical formulation.
  • the solid forms can be mixed with pharmaceutically acceptable adjuvants, diluents or carriers.
  • the amount of solid Forms 1 or 2 of Siponimod Fumaric acid (1 : 1) salt or solid Forms 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9, in the formulation depends on the condition and a patient to be treated.
  • the pharmaceutical formulation can be if form of a solid oral formulation, for example a capsule, a pill, a powder or a granule.
  • the Siponimod salts according to presented invention can be mixed with one or more additives such as fillers or extenders or binders or wetting agents or disintegrating agents or absorbents or lubricants or buffering agents.
  • the formulation in a form of a tablet or a dragee or a capsule or a pill or a granule can be coated with a coating or shell such as enteric or other coating.
  • the oral formulation can be in a form of an oral emulsion or a solution or a suspension or a syrup.
  • the formulation can contain suitable additives such as diluent(s) or wetting agent(s) or emulsifying agent(s) or suspending agent(s) or sweetening agent(s) or flavoring agent(s).
  • suitable additive(s) are known to those skilled in the art.
  • the suitable pharmaceutical formulation can be in a parenteral form such as an injection or an infusion or an injectable depot or in a liposomal form comprising
  • the pharmaceutical formulation can be also in a form of a powder for reconstitution into an injection or infusion.
  • the formulation can further comprise additives such as preservative(s) or wetting agent(s) or emulsifying agent(s) or dispersing agent(s) or antibacterial or antifungal agents.
  • suitable additive(s) are known to those skilled in the art.
  • the suitable pharmaceutical formulation can be in a form suitable for rectal or vaginal administration further comprising suitable additive(s).
  • suitable additive(s) are known to those skilled in the art.
  • the solid forms 1 or 2 of Siponimod Fumaric acid (1 : 1) salt or solid forms 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 of Siponimod maleic acid (1 : 1) salt or a pharmaceutical formulation comprising the forms can be used for the treatment of conditions treatable with Siponimod or a salt thereof.
  • the compound of formula (I) can be prepared by a process disclosed in
  • the amorphous form of compound of formula (I) can be prepared by a process known from the prior art or by a procedure described in Example 1.
  • XRPD spectrum of solid compounds was obtained using the following measurement conditions: Panalytical Empyrean diffractometer with Q/2Q geometry (transmition mode), equipped with a PixCell 3D detector
  • DCS patterns were obtained using the following conditions: 10°C/min -> 250°C
  • Example 1 Preparation of Sinonimod Fumaric acid (1 : 1) salt.
  • amorphous Siponimod 0.4 g was mixed with 2 ml of ethanol. The reaction mixture was heated to 60°C to obtain a solution. 0.09 g of Fumaric acid was added to the mixture.
  • amorphous Siponimod was mixed with 0.09 g of Fumaric acid and 2 ml of ethanol. The reaction mixture was heated to 40°C to obtain a solution. The mixture was concentrated at 40°C to dryness by vacuum to obtain 0.32 g of Siponimod Fumaric acid (1 : 1) salt, Form 1.
  • XRPD pattern of obtained solid corresponds to XRPD pattern depicted in Figure 1.
  • DSC pattern of obtained solid corresponds to DSC pattern depicted in Figure 2.
  • amorphous Siponimod was mixed with 8 ml of 2-propanol. 0.09 g of Fumaric acid was added to the mixture. The reaction mixture was heated to 75 °C to obtain a solution. The mixture was cooled to 0°C and stirred at this temperature over weekend. Precipitated solid was filtered and dried in dryer (25°C, 3 hours, vacuum) to obtain 0.34 g of Siponimod Fumaric acid (1: 1) salt, Form 2.
  • XRPD pattern of obtained solid corresponds to XRPD pattern depicted in Figure 3.
  • DSC pattern of obtained solid corresponds to DSC pattern depicted in Figure 4.
  • amorphous Siponimod was mixed with 5 ml of isopropyl acetate. The mixture was stirred at 25°C for 15 minutes to obtain a solution. 0.09 g of Maleic acid was added to the mixture. The reaction mixture stirred at 25 °C for 45 minutes to obtain a suspension. The suspension was filtered and dried in dried in dryer (25°C, 1 hours, vacuum) to obtain 0.37 g of Siponimod Maleic acid (1: 1) salt, Form 1.
  • XRPD pattern of obtained solid corresponds to XRPD pattern depicted in Figure 5.
  • DSC pattern of obtained solid corresponds to DSC pattern depicted in Figure 6.
  • amorphous Siponimod was mixed 0.09 g of Maleic acid and 7 ml of methyl tert-butyl ether. The mixture was stirred at 25°C for 30 minutes. The suspension was filtered and dried in dried on filter (25°C, 1 hours, vacuum) to obtain 0.38 g of Siponimod Maleic acid (1 :1) salt, Form 1.
  • XRPD pattern of obtained solid corresponds to XRPD pattern depicted in Figure 5.
  • DSC pattern of obtained solid corresponds to DSC pattern depicted in Figure 6.
  • XRPD pattern of obtained solid corresponds to XRPD pattern depicted in Figure 5.
  • DSC pattern of obtained solid corresponds to DSC pattern depicted in Figure 6.
  • Example 9 Preparation of Siponimod Maleic acid (1 : 1) salt.
  • amorphous Siponimod was mixed with 8 ml of methyl tert-butyl ether. The mixture was stirred for 15 minutes at 25°C. 0.09 g of Maleic acid was added. The mixture was stirred at 25°C over weekend. The suspension was filtered and dried in dried in dryer (25°C, 1 hour, vacuum) to obtain 0.38 g of Siponimod Maleic acid (1 :1) salt, Form 3.
  • XRPD pattern of obtained solid corresponds to XRPD pattern depicted in Figure 7.
  • DSC pattern of obtained solid corresponds to DSC pattern depicted in Figure 8.
  • amorphous Siponimod was mixed with 8 ml of cyclohexane. The mixture was stirred for 15 minutes at 25°C. 0.09 g of Maleic acid was added. The mixture was stirred at 25°C over weekend. The suspension was filtered and dried in dried in dryer (25°C, 1 hour, vacuum) to obtain 0.37 g of Siponimod Maleic acid (1 : 1) salt, Form 4.
  • XRPD pattern of obtained solid corresponds to XRPD pattern depicted in Figure 9.
  • DSC pattern of obtained solid corresponds to DSC pattern depicted in Figure 10.
  • amorphous Siponimod was mixed with 2.5 ml of methanol. The mixture was stirred for 15 minutes at 25°C. 0.112 g of Maleic acid was added and stirred for 15 minutes. The solution was concentrated to dryness in dryer (25°C/12 h/vacuum). The rest was mixed with 4 ml of ethylacetate and left without stirring to crystallize (25°C, 1 hour). The suspension was decanted and the rest was dried on XRPD holder (25°C/30 min/vacuum) to obtain 0.35 g of Siponimod Maleic acid (1: 1) salt, Form 5.
  • XRPD pattern of obtained solid corresponds to XRPD pattern depicted in Figure 11.
  • DSC pattern of obtained solid corresponds to DSC pattern depicted in Figure 12.
  • Example 13 Preparation of Siponimod Maleic acid (1 : 1) salt.
  • Form 6 and Form 7 0.5 g of amorphous Siponimod was mixed with 2.5 ml of methanol. The mixture was stirred for 15 minutes at 25°C. 0.112 g of Maleic acid was added and stirred for 15 minutes. The solution was concentrated to dryness in dryer (25°C/12 h/vacuum). The rest was mixed with 2 ml of water and left without stirring to crystallize (25°C, 1 hour). The wet solid was analyzed and it corresponds to Form 7 of Siponimod Maleic acid (1: 1) salt. XRPD pattern of obtained solid corresponds to XRPD pattern depicted in Figure 15.
  • Siponimod maleic acid salt prepared according to Example 4 was mixed with 10 ml of water. The mixture was heated at 60°C for 2 hours, then cooled to 25 °C and filtered. The product was dried under vacuum over the night. Siponimod maleic acid salt, Form 8 was obtained in quantitative yield.
  • XRPD pattern of obtained solid corresponds to XRPD pattern depicted in Figure 18.
  • DSC pattern of obtained solid corresponds to DSC pattern depicted in Figure 19.
  • Siponimod maleic acid salt prepared according to Example 13 2 g was mixed with 10 ml of water and left standing for 1/2 year. Obtained solid was filtered off and dried on air overnight. Siponimod maleic acid salt, Form 9 was obtained in quantitative yield.
  • XRPD pattern of obtained solid corresponds to XRPD pattern depicted in Figure 20.
  • DSC pattern of obtained solid corresponds to DSC pattern depicted in Figure 21.
  • Prior art Siponimod Fumarate (1 :0.5), Form A was prepared according to a procedure disclosed in WO2010/080409. Water activity of the prior art form and solid forms of presented invention was measured: DVS machine ProUmid SPX-Im Advance, 25°C, 0-90-0 % relative humidity, step 10%, maximal time per step 10 hours. Equilibrium bandwidth 0.05%/60 minutes.
  • Water activity a difference between the weights of the sample in 0 and 90% of relative humidity at a constant temperature. It corresponds to the amount of water taken by
  • Siponimod salt when the humidity changes from 0 to 90% at a constant temperature.
  • the higher water activity the more water can be taken by the compound and that might result in lower purity of the compound because hydrolysis impurities can be formed. It can also result in mechanical stress in final products (for example tablets) because the compound taking water increases its volume and the volume of the final product (for example tablet) is also increased and that results in cracking of the product.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des sels de siponimod avec de l'acide fumarique (1:1) et des formes solides 1 et 2 de ceux-ci. La présente invention concerne en outre des sels de siponimod avec de l'acide maléique (1:1) et des formes solides 1, 2, 3, 4, 5, 6, 7, 8 et 9 de ceux-ci.
PCT/EP2020/064211 2019-05-21 2020-05-21 Sel d'acide maléique et d'acide fumarique siponimod Ceased WO2020234423A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20726476.3A EP3972954A1 (fr) 2019-05-21 2020-05-21 Sel d'acide maléique et d'acide fumarique siponimod

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19175593.3 2019-05-21
EP19175593 2019-05-21

Publications (1)

Publication Number Publication Date
WO2020234423A1 true WO2020234423A1 (fr) 2020-11-26

Family

ID=66625838

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/064211 Ceased WO2020234423A1 (fr) 2019-05-21 2020-05-21 Sel d'acide maléique et d'acide fumarique siponimod

Country Status (2)

Country Link
EP (1) EP3972954A1 (fr)
WO (1) WO2020234423A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11673860B2 (en) 2018-01-22 2023-06-13 Teva Pharmaceuticals International Gmbh Crystalline siponimod fumaric acid and polymorphs thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103306A2 (fr) 2003-05-19 2004-12-02 Irm Llc Composes immunosuppresseurs et compositions
WO2010080409A1 (fr) 2008-12-18 2010-07-15 Novartis Ag Sel hémifumarate d'acide 1-[4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino]-éthyl]-2-éthyl-benzyl]-azétidine-3-carboxylique
WO2010080455A1 (fr) 2008-12-18 2010-07-15 Novartis Ag Nouveaux sels
WO2016059571A1 (fr) * 2014-10-16 2016-04-21 Novartis Ag Combinaisons comprenant du siponimod et du laquinimod pour le traitement de la sclérose en plaques
WO2019064184A1 (fr) * 2017-09-27 2019-04-04 Dr. Reddy's Laboratories Limited Procédé de préparation de siponimod, de ses sels et de formes à l'état solide associées
WO2019064217A1 (fr) * 2017-09-29 2019-04-04 Novartis Ag Schéma posologique de siponimod
WO2019064212A1 (fr) * 2017-09-29 2019-04-04 Novartis Ag Schéma posologique de siponimod

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103306A2 (fr) 2003-05-19 2004-12-02 Irm Llc Composes immunosuppresseurs et compositions
WO2010080409A1 (fr) 2008-12-18 2010-07-15 Novartis Ag Sel hémifumarate d'acide 1-[4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino]-éthyl]-2-éthyl-benzyl]-azétidine-3-carboxylique
WO2010080455A1 (fr) 2008-12-18 2010-07-15 Novartis Ag Nouveaux sels
WO2016059571A1 (fr) * 2014-10-16 2016-04-21 Novartis Ag Combinaisons comprenant du siponimod et du laquinimod pour le traitement de la sclérose en plaques
WO2019064184A1 (fr) * 2017-09-27 2019-04-04 Dr. Reddy's Laboratories Limited Procédé de préparation de siponimod, de ses sels et de formes à l'état solide associées
WO2019064217A1 (fr) * 2017-09-29 2019-04-04 Novartis Ag Schéma posologique de siponimod
WO2019064212A1 (fr) * 2017-09-29 2019-04-04 Novartis Ag Schéma posologique de siponimod

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11673860B2 (en) 2018-01-22 2023-06-13 Teva Pharmaceuticals International Gmbh Crystalline siponimod fumaric acid and polymorphs thereof

Also Published As

Publication number Publication date
EP3972954A1 (fr) 2022-03-30

Similar Documents

Publication Publication Date Title
US9789125B2 (en) Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
EA009736B1 (ru) Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение в качестве лекарственного средства
US10150770B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
JP2008509953A (ja) ４−［［（７ｒ）−８−シクロペンチル−７−エチル−５，６，７，８−テトラヒドロ−５−メチル−４−６−オキソ−２−ピペリジニル］アミノ］−３−メトキシ−ｎ−（１−メチル−４−ピペリジニル）ベンズアミドの水和物及び多形、その製造方法、並びにその薬物としての使用
US9221815B2 (en) Solid state form of vemurafenib choline salt
JP2018501289A (ja) ネラチニブマレイン酸塩の新規な結晶形及びその製造方法
WO2014008794A1 (fr) Forme cristallisée i du dimaléate inhibiteur de tyrosine kinase et ses méthodes de préparation
CN108290824A (zh) 索拉贝隆两性离子及其应用
BG108344A (bg) ЦИТРАТНА СОЛ НА 5.8.14-ТРИАЗАТЕТРАЦИКЛО-(10.3.1.0на степен2,11 .0на степен4.9)- ХЕКСАДЕКА-2.(11),3,5,7,9-ПЕНТАЕН И НЕЙНИ ФАРМАЦЕВТИЧНИ СЪСТАВИ
WO2020234423A1 (fr) Sel d'acide maléique et d'acide fumarique siponimod
NO770152L (no) Fremgangsm}te for fremstilling av fysiologisk aktive p-benzylaminobenzoesyre-derivater.
EP3595671A1 (fr) Sels d'analogues de phosphonate antiviraux et leur procédé de préparation
WO2005102999A2 (fr) Formes cristallines d'hydrochlorure de fexofenadine, et procedes pour les preparer
US20120309990A1 (en) Processes for the Purification of Lubiprostone
WO2004002472A1 (fr) Hydobromure de carvedilol
WO2012013118A1 (fr) Cristaux de sulfate de carvédilol, leur procédé de synthèse et leurs applications pharmaceutiques
US20230036336A1 (en) Crystalline forms of sodium salt of bempedoic acid
US20210251964A1 (en) Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
WO2022064007A1 (fr) Sels et co-cristaux de siponimod
WO2020208167A1 (fr) Formes solide de siponimod
JP2025536048A (ja) アシミニブ塩酸塩の結晶形態
US20230118152A1 (en) Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
US20110251286A1 (en) Crystalline salts and/or co-crystals of O-desmethyltramadol
CA2989364C (fr) Procede de preparation de citrate d'enclomiphene ayant un habitus aciculaire.
TW201319042A (zh) 硫酸卡維地洛的結晶、其製備方法及其在醫藥上的應用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20726476

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020726476

Country of ref document: EP

Effective date: 20211221